More important than potential, look at the financials bottom line. Anyone offered a billion cash and securities for lock, stock and barrel, and turns it down for a better offer, is an idiot. There’s nothing wrong with 2.50 a share for a company with $400 million invested and currently trading at 1/12th the price. Otherwise, show me that it’s worth more for a company with one marketable drug in development. I’m all ears.